Eribulin mesylate

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer (label: metastatic breast cancer of any HR or HER2 status, after two or more prior chemotherapy regimens), Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Unresectable or metastatic liposarcoma after an anthracycline-containing regimen
Product first approved 2010Outside this platform's coverageFDA label
JP
  • Treatment of inoperable or recurrent breast cancer
Product first approved 2011PMDA
EU
  • Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1).
Product first approved 2011EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (17)
Breast Cancer
NCT06889688 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-02-21 – 2029-06-01 · Breast Cancer Stage IV, Triple -Negative Breast Cancer
What this study did
NCT06382142 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-06-21 – 2027-12 · Triple-Negative Breast Cancer
What this study did
NCT05760378 · Fudan University
2023-03-17 – 2027-01-01 · Triple-Negative Breast Cancer
What this study did
NCT05134194 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-01-17 – 2022-12-15 · Triple Negative Breast Cancer
What this study did
NCT02514681 · Japan Breast Cancer Research Group
2015-08-01 – 2022-08-10 · HER2-positive Locally Advanced or Metastatic Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06343948 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-04-24 – 2027-12 · HR+HER2- Breast Cancer
What this study did
NCT02344472 · Prof. Wolfgang Janni
2015-09 – 2025-01-31 · Metastatic Breast Cancer
What this study did
NCT03264547 · Japan Breast Cancer Research Group
2017-08-28 – 2024-12-31 · Breast Cancer
What this study did
NCT02037529 · Academic and Community Cancer Research United
2014-01-17 – 2024-10-31 · Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
What this study did
Other / comorbidity
NCT04579224 · National Cancer Institute (NCI)
2021-06-28 – 2027-10-29 · Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
What this study did
NCT01327885 · Eisai Inc.
2011-03-10 – 2016-08-10 · Soft Tissue Sarcoma
What this study did
Phase 2 (89)
Breast Cancer
NCT07007559 · ALX Oncology Inc.
2025-12-10 – 2028-12 · Breast Cancer, Metastatic
What this study did
NCT07333937 · Xijing Hospital
2025-12-20 – 2028-11-20 · Brest Cancer
What this study did
NCT07441512 · Hu Hai
2026-03-15 – 2028-03-15 · TNBC - Triple-Negative Breast Cancer, TNBC
What this study did
NCT06731153 · Fudan University
2024-12 – 2027-12 · Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer
What this study did
NCT05458674 · Criterium, Inc.
2024-01-30 – 2027-08-01 · Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
What this study did
NCT07255612 · Sun Yat-sen University
2026-11-04 – 2026-12-01 · Breast Cancer
What this study did
NCT05945368 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-02-25 – 2025-02-25 · HER2-positive Breast Cancer
What this study did
NCT06355037 · Fudan University
2024-05-20 – 2025-01-31 · Triple-negative Breast Cancer
What this study did
NCT06355024 · Fudan University
2024-05-11 – 2025-01-01 · Triple-negative Breast Cancer
What this study did
NCT04681911 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2020-09-09 – 2024-09-09 · Breast Cancer
What this study did
NCT04502680 · The First Affiliated Hospital with Nanjing Medical University
2021-06 – 2024-06 · Triple Negative Breast Cancer
What this study did
NCT05546255 · Chinese Academy of Medical Sciences
2020-06-01 – 2023-12-31 · Triple Negative Breast Cancer
What this study did
NCT04464174 · MedSIR
2020-10-08 – 2023-11-10 · Triple Negative Breast Cancer
What this study did
NCT04303741 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2020-03-25 – 2023-08-31 · Breast Cancer
What this study did
NCT05402722 · Beijing 302 Hospital
2022-01-01 – 2023-06-30 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT04517292 · Fudan University
2020-10-08 – 2022-10-31 · Breast Cancer
What this study did
NCT01372579 · Northwestern University
2011-08 – 2021-06 · Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
What this study did
NCT01593020 · M.D. Anderson Cancer Center
2012-08-03 – 2020-11-04 · Breast Cancer
What this study did
NCT02215876 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2014-09 – 2020-03 · Breast Cancer
What this study did
NCT01328249 · Eisai Inc.
2011-03-03 – 2017-10-19 · HER2-normal
What this study did
NCT01912963 · Dana-Farber Cancer Institute
2013-09 – 2016-12 · HER2-positive Breast Cancer, Metastatic Breast Cancer
What this study did
NCT01269346 · Eisai Inc.
2010-12 – 2016-05 · Breast Cancer
What this study did
NCT01669252 · SOLTI Breast Cancer Research Group
2012-08 – 2015-06 · Breast Cancer
What this study did
NCT01439282 · Eisai Inc.
2011-08 – 2014-05 · Estrogen Receptor Positive Tumor, Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT04986579 · Dana-Farber Cancer Institute
2021-10-07 – 2030-06-01 · Metastatic Breast Cancer, Chemotherapy-induced Alopecia
What this study did
NCT06449222 · BioNTech SE
2024-08-26 – 2029-06 · Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
What this study did
NCT05530057 · Seoul National University Hospital
2020-02-18 – 2028-06-30 · Advanced Breast Cancer
What this study did
NCT03202316 · M.D. Anderson Cancer Center
2017-08-11 – 2027-12-31 · Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
What this study did
NCT05810870 · MedSIR
2023-05-24 – 2027-07 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT06387628 · Fudan University
2024-07-10 – 2027-04-01 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT02623972 · Dana-Farber Cancer Institute
2016-02-26 – 2026-12 · Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
What this study did
NCT06678230 · The First Hospital of Jilin University
2024-11 – 2025-10-20 · Breast Cancer
What this study did
NCT05263882 · Fifth Affiliated Hospital, Sun Yat-Sen University
2022-03 – 2024-09 · HER2-negative Breast Cancer
What this study did
NCT02035813 · Prof. Wolfgang Janni
2014-01 – 2024-01-10 · HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients
What this study did
NCT03051659 · Dana-Farber Cancer Institute
2017-03-22 – 2023-09-05 · Breast Cancer
What this study did
NCT05833919 · Consorzio Oncotech
2018-07-30 – 2023-07 · Metastatic Breast Cancer
What this study did
NCT04624711 · The First Affiliated Hospital with Nanjing Medical University
2021-03-01 – 2022-12 · HER2-negative Breast Cancer
What this study did
NCT02404506 · Swiss Cancer Institute
2015-08-17 – 2021-07-22 · Breast Cancer, Adenocarcinoma
What this study did
NCT03795012 · MedSIR
2019-04-30 – 2021-03-31 · Breast Cancer
What this study did
NCT03222856 · MedSIR
2017-12-14 – 2020-12-23 · Breast Cancer
What this study did
NCT02581839 · Case Comprehensive Cancer Center
2015-11-17 – 2020-07-02 · Metastatic Breast Cancer, Brain Metastases
What this study did
NCT03032614 · The University of Texas Health Science Center at San Antonio
2017-09-30 – 2020-04-30 · Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation
What this study did
NCT03412955 · Tan Tock Seng Hospital
2017-03-08 – 2020-04-30 · Breast Cancer
What this study did
NCT03637868 · Institut Paoli-Calmettes
2019-02-26 – 2020-04-14 · Metastatic Breast Cancer
What this study did
NCT02263495 · Asan Medical Center
2014-12-19 – 2019-06-17 · Metastatic Breast Cancer
What this study did
NCT01908101 · University of Washington
2014-01-08 – 2019-05-04 · Recurrent Breast Carcinoma, Stage IV Breast Cancer
What this study did
NCT02681523 · Imperial College London
2015-10-28 – 2018-07-24 · Breast Cancer
What this study did
Phase 1/2 (23)
Breast Cancer
NCT07494448 · MedSIR
2026-07-01 – 2028-05-31 · HER 2 Positive Advanced Breast Cancer, Breast Cancer
What this study did
NCT04345913 · National Cancer Institute (NCI)
2021-03-01 – 2027-05-31 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT01388647 · Vector Oncology
2011-08 – 2014-09 · HER-2 Positive Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07811232 · Advenchen Pharmaceuticals, LLC.
2026-09-01 – 2031-09-01 · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
What this study did
NCT06942234 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2025-06-01 – 2027-12-31 · Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
What this study did
NCT05824975 · GI Innovation, Inc.
2023-05-30 – 2027-04-24 · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
What this study did
NCT05335473 · Henan Cancer Hospital
2022-05-13 – 2026-09-01 · HR Positive HER2 Negative Advanced Breast Cancer
What this study did
NCT05041101 · M.D. Anderson Cancer Center
2021-12-21 – 2024-09-06 · Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
What this study did
NCT04826016 · MedSIR
2022-03-16 – 2022-03-16 · Advanced Breast Cancer
What this study did
NCT01554371 · University of California, San Francisco
2012-03-27 – 2019-12-31 · Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, Neuropathy
What this study did
NCT01596751 · Hope Rugo, MD
2012-07-12 – 2019-07-05 · Metastatic Breast Cancer
What this study did
NCT02723877 · PIQUR Therapeutics AG
2016-03-28 – 2018-10-03 · Metastatic Breast Cancer
What this study did
NCT01323530 · Eisai Limited
2010-01-26 – 2015-10-13 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT00365157 · National Cancer Institute (NCI)
2006-10-23 – 2027-07-09 · Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Unresectable Urothelial Carcinoma
What this study did
NCT04078295 · Eisai Co., Ltd.
2019-09-05 – 2027-03-31 · Solid Neoplasms
What this study did
NCT03526679 · National Taiwan University Hospital
2018-07-12 – 2025-10-30 · Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult, Advanced Cancer
What this study did
NCT03245450 · Eisai Inc.
2018-03-05 – 2021-05-17 · Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
What this study did
NCT01744340 · howard safran
2012-05 – 2015-07 · Head and Neck Cancer, Colon Cancer
What this study did
NCT02396433 · The University of Texas Health Science Center at San Antonio
2015-04 – 2015-04 · Cancer of the Breast
What this study did
Phase 1 (38)
Breast Cancer
NCT06328738 · Enliven Therapeutics
2024-05-30 – 2028-07 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
What this study did
NCT06590558 · National Cancer Institute (NCI)
2025-08-04 – 2027-05-17 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Negative Breast Carcinoma, Locally Advanced Hormone Receptor-Positive Breast Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT03579472 · M.D. Anderson Cancer Center
2018-05-30 – 2022-09-21 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT02120469 · City of Hope Medical Center
2014-11-17 – 2020-03-03 · Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative, Stage IV Breast Cancer, Triple-negative Breast Carcinoma
What this study did
NCT02014337 · Corcept Therapeutics
2014-01 – 2017-12 · Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms
What this study did
NCT02616848 · Istituti Ospitalieri di Cremona
2015-11 – 2015-11 · Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT01795586 · H. Lee Moffitt Cancer Center and Research Institute
2013-02-06 – 2022-05-11 · Breast Cancer
What this study did
NCT02824575 · Montefiore Medical Center
2016-07 – 2021-12-27 · Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Carcinoma, Stage IV Breast Cancer
What this study did
NCT03430518 · Amy Tiersten
2018-05-17 – 2020-02-10 · HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer
What this study did
NCT01837095 · Polyphor Ltd.
2013-06 – 2018-08 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT06957431 · Washington University School of Medicine
2025-10-22 – 2036-04-30 · Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced Liposarcoma
What this study did
NCT03361436 · OHSU Knight Cancer Institute
2018-03-19 – 2033-04-14 · Liposarcoma, Malignant Abdominal Neoplasm, Malignant Retroperitoneal Neoplasm, Malignant Scrotal Neoplasm, Malignant Solid Neoplasm, Malignant Spermatic Cord Neoplasm
What this study did
NCT06006273 · M.D. Anderson Cancer Center
2023-08-16 – 2028-12-31 · Refractory Solid Tumors
What this study did
NCT03207672 · Eisai Co., Ltd.
2017-08-18 – 2027-03-31 · Solid Tumor
What this study did
NCT02419495 · M.D. Anderson Cancer Center
2015-06-26 – 2024-09-16 · Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
What this study did
NCT02338037 · City of Hope Medical Center
2015-09-16 – 2024-03-15 · Metastatic Malignant Neoplasm in the Adult Brain, Primary Brain Tumor
What this study did
NCT04013217 · Health Hope Pharma
2019-07-29 – 2022-03-02 · Solid Tumor
What this study did
NCT02596503 · University of Colorado, Denver
2015-10-21 – 2020-01-24 · Relapsed Solid Tumors, Refractory Solid Tumors
What this study did
NCT03502681 · Monika Joshi, MD
2018-06-12 – 2019-10-25 · Metastatic Urothelial Cell Cancer
What this study did
NCT02082626 · University of Oklahoma
2014-02-01 – 2018-06 · Pediatric Cancer, Solid Tumors, Lymphoma
What this study did
NCT01585870 · Bayer
2012-07 – 2015-09 · Neoplasms
What this study did
NCT01418677 · Eisai Inc.
2011-10 – 2015-05 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00415324 · National Cancer Institute (NCI)
2006-12 – 2014-05 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00410553 · National Cancer Institute (NCI)
2006-11-14 – 2012-10-24 · Adult Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7
What this study did
NCT00268905 · Eisai Inc.
2006-10 – 2011-11 · Cancer
What this study did
NCT03002493 · Eisai Limited
2009-12 – 2011-06 · Tumor
What this study did
NCT00908908 · Eisai Inc.
2009-03 – 2011-05 · Advanced Solid Tumors
What this study did
NCT01106248 · Eisai Limited
2009-03 – 2010-09 · Advanced Solid Tumor
What this study did
NCT00326950 · Eisai Co., Ltd.
2006-06 – 2008-02 · Cancer
What this study did
NCT00047034 · National Cancer Institute (NCI)
2002-08 – 2007-10 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00069264 · Eisai Inc.
2003-09 – 2005-07 · Advanced Solid Tumors
What this study did
NCT00069277 · Eisai Inc.
2003-08 – 2005-04 · Cancer
What this study did
Phase 4 (4)
HR+/HER2- Metastatic Breast Cancer
NCT05033769 · Institut fuer Frauengesundheit
2021-03-11 – 2023-09-15 · Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic
What this study did
NCT02864030 · Oncologia Medica dell'Ospedale Fatebenefratelli
2014-05 – 2020-12-31 · Metastatic Breast Cancer, Toxicity, Neurotoxicity, Drug Toxicity, Adverse Drug Event
What this study did
NCT01961544 · Eisai Korea Inc.
2013-06 – 2015-07 · Breast Neoplasms, Breast Cancer
What this study did
Early phase / not applicable (2)
HR+/HER2- Metastatic Breast Cancer
NCT02841722 · Centre Georges Francois Leclerc
2015-12-03 – 2020-01-10 · Breast Cancer
What this study did
NCT01142661 · Eisai Inc.
2010-08 – 2011-08 · Breast Cancer
What this study did
Used as active comparator (27)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (24)
Breast Cancer
NCT07533123 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2026-03-17 – 2030-03-17 · Triple Negative Breast Cancer
What this study did
NCT07879911 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-11-30 – 2029-05-30 · Triple Negative Breast Cancer
What this study did
NCT06279364 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-02-28 – 2028-12 · Triple Negative Breast Cancer
What this study did
NCT06519370 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
2024-08-09 – 2027-06-20 · Triple Negative Breast Cancer
What this study did
NCT05063786 · Spanish Breast Cancer Research Group
2021-09-14 – 2025-12-23 · Advanced Breast Cancer
What this study did
NCT02574455 · Gilead Sciences
2017-11-07 – 2020-12-08 · Breast Cancer
What this study did
NCT02555657 · Merck Sharp & Dohme LLC
2015-10-13 – 2020-11-10 · Metastatic Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06255392 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-06-12 – 2031-03 · Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
What this study did
NCT07406542 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-04-01 – 2030-04-01 · Recurrent or Metastatic Breast Cancer
What this study did
NCT06079983 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2023-12-01 – 2029-03-01 · Breast Cancer
What this study did
NCT06383767 · Qilu Pharmaceutical Co., Ltd.
2024-07-11 – 2028-07-31 · Metastatic Breast Cancer
What this study did
NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-03-17 – 2028-06-30 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT05814354 · Jiangsu HengRui Medicine Co., Ltd.
2023-06-30 – 2028-06-30 · Breast Cancer
What this study did
NCT06143553 · Shanghai Yizhong Pharmaceutical Co., Ltd.
2023-09-25 – 2028-06-30 · Metastatic Breast Cancer (MBC)
What this study did
NCT06268652 · Sun Yat-sen University
2024-01-15 – 2028-01-15 · Breast Cancer, Refractory Breast Carcinoma
What this study did
NCT06081959 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2023-10-31 – 2027-12-31 · Metastatic Breast Cancer
What this study did
NCT06957886 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-05-15 – 2027-12 · HER2-low Breast Cancer
What this study did
NCT04639986 · Gilead Sciences
2020-11-23 – 2026-12 · Metastatic Breast Cancer
What this study did
NCT03901339 · Gilead Sciences
2019-05-08 – 2023-10-20 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT06263231 · Intensity Therapeutics, Inc.
2024-06-28 – 2028-12 · Sarcoma,Soft Tissue
What this study did
Phase 2 (3)
Breast Cancer
NCT04745975 · Fudan University
2021-02-01 – 2023-01 · Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06102824 · Guangdong Provincial People's Hospital
2024-10-01 – 2028-06-30 · HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
NCT02299999 · UNICANCER
2014-04-07 – 2025-12 · Metastatic Breast Cancer
What this study did
Appears in other studies (13)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Breast Cancer
NCT07173751 · BioNTech SE
2025-10-30 – 2030-09 · Breast Neoplasms
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07088263 · Sun Yat-sen University
2025-09-15 – 2028-06-24 · Breast Neoplasms
What this study did
NCT03786094 · Spexis AG
2019-05-30 – 2021-10-19 · Metastatic Breast Cancer, Locally Recurrent Breast Cancer
What this study did
Phase 2 (8)
Breast Cancer
NCT07824869 · Shanghai Henlius Biotech
2026-10-31 – 2029-12-04 · HER2 + Breast Cancer
What this study did
NCT06202313 · Shengjing Hospital
2024-02-10 – 2028-12-30 · Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05570253 · Memorial Sloan Kettering Cancer Center
2022-10-03 – 2027-10 · Breast Cancer, Metastatic Triple-Negative Breast Cancer
What this study did
NCT06539559 · Wang Jiayu
2024-08-01 – 2026-08-01 · Breast Neoplasms, Neoplasm Metastasis, Drug Therapy, Bevacizumab
What this study did
NCT06533722 · Sun Yat-sen University
2024-08-04 – 2025-05-28 · HER2-negative Metastatic Breast Cancer
What this study did
NCT05206656 · Hunan Cancer Hospital
2020-10-09 – 2022-07-20 · Metastatic Breast Cancer
What this study did
NCT01427933 · Eli Lilly and Company
2011-11 – 2014-06 · Breast Cancer
What this study did
Phase 1/2 (2)
HR+/HER2- Metastatic Breast Cancer
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT06202261 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-04-13 – 2027-10 · Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
What this study did

Competitive landscape

Other Tubulin / microtubules drugs

Utidelone. Compare all 2 Tubulin / microtubules drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Eribulin Mesylate: this drugApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Eribulin mesylate to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2026-12-01 · NCT07255612 · CT.gov ↗
What to watch
Phase 1Refractory Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT06006273 · CT.gov ↗
What to watch
2027 (11)
January 2027 (1)
Phase 1Breast CancerActive not recruiting
Est. primary completion 2027-01 · NCT06328738 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1/2Solid NeoplasmsActive not recruiting
Est. primary completion 2027-03-31 · NCT04078295 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-06 · NCT06731153 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT05458674 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06942234 · CT.gov ↗
What to watch
Phase 2Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma …Active not recruiting
Est. primary completion 2027-06-30 · NCT03237780 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-11-20 · NCT07333937 · CT.gov ↗
What to watch
December 2027 (4)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12 · NCT07007559 · CT.gov ↗
What to watch
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07494448 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcoma (STS)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07205185 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT03202316 · CT.gov ↗
What to watch
2028 (6)
March 2028 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-03-15 · NCT07441512 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2028-04-28 · NCT06435429 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT04986579 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT05530057 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-08 · NCT06449222 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06889688 · CT.gov ↗
What to watch
2030 (2)
April 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-04-30 · NCT07520760 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-09-01 · NCT07811232 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Phase 1Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced LiposarcomaRecruiting
Est. primary completion 2031-05-31 · NCT06957431 · CT.gov ↗
What to watch

See the full readout calendar ↗